13 Feb Life Cycle of Malarial Parasites and Pathogenecity.
Malaria is one of the fatal disease in human, caused by a protozoan named Plasmodium and spread by Female Anopheles Mosquito, as one of the host of pathogen other than human.
According to the World Health Organization (WHO) World Malaria Report 2025
- Global Burden: There were an estimated 282 million cases and 610,000 deaths in 2024, a slight increase from previous years due to population growth and service disruptions.
- Geographic Concentration: The WHO African Region carries a disproportionate share, accounting for 95% of all cases and 96% of deaths.
- Vulnerable Populations: Children under the age of 5 remain the most affected, accounting for approximately 76% of all malaria deaths in the African region.
- High-Impact Countries: Over half of all global deaths occur in just three countries: Nigeria (31.9%), the Democratic Republic of the Congo (11.7%), and Niger (6.1%).
- In 2024, India exited the WHO’s “High Burden to High Impact” (HBHI) group. India contributes around 0.7% to 0.8% of Global Malaria cases.
There are mainly 4 species of Plasmodium which cause disease Plasmodium falciparum, Plasmodium vivax Plasmodium ovale and Plasmodium malariae. They have different level of pathogenecity as P. falciparum causes “malignant tertian” malaria, responsible for most of the deaths through high density parasitemia, with vascular sequestration, leading to severe anaemia, cerecral malaria, while P. vivax causes benign malaria with comparatively lower mortality rates. Others are mainly zoonotic.
Life Cycle of Malarial Parasite– Plasmodium falciparum is digenetic, meaning it completes its life cycle into two hosts: human and mosquito (female Anopheles). It is an intracellular parasite in man living in red blood corpuscles and liver cells, while extracellular in mosquito, living in its alimentary canal and salivary gland.
In Human (Primary host) – A healthy person acquires infection when a female Anopheles mosquito bites, containing infective stages of Plasmodium i.e sporozites in its salivary gland. Sporozite is the infective stage in human. After entering into blood, sporozites Schizogony moves to liver and invade hepatic cells. Here they multiply asexually. In liver, the Pre-erythrocytic phase starts where after penetrating in the hepatic cell, sporozoites grow by taking nutrition and are now known as cryptozoite. This spherical and non pigmented become schizont. They divide by schizony (multiple fission) and forms a large number(varry) of uninucleate cells, the cryptomerozite. These are liberated when liver cells burst and become metacryptozoites and repeat the process.
Metacryprozites move to bloodstream and invade the erythrocytes/RBCs and forms diferent stages a. Trophozoite stage– Inside RBCs the metacryptozoites become rounded and modified into young trophozoite. They are actively feeding stage of Plasmodium, consuming nutrients from the host blood cells. b.Signet ring stage– As the trophozite grows in size, a central vacuole developed, which pushed nucleus into one side into cytoplasm. This resembles with signet ring, looks like the gem of the ring. c.Amoeboid stage– Trophozoite stage further develop into active amoeboid trophozoite. This stage is an indicator of malaria infection due the the presence of Schuffner’s granules. As small red eosinophilic granules appear in the cytoplasm of host’s RBCs, by the metabolic activity and byproducts of parasites and host’s immune response against it. The amoeboid trophozite further grows and its nucleus divides to form 12-24 nuclei and arranged at the periphery and becomes oval shaped merozite. with the rupture of the RBCs, merozites are liberated into blood plasma. Infected/destruction of erythrocytes on liberation of merozites causing malarial fever and also anaemic situation. This stage causes the clinical symptoms (fever, chills, anemia).
Once the impulse to multiply asexually exhausted, the merozites do not proceed ahead with erythrocytic cycle, but increase their size to become rounded gametocytes. Some parasites differentiate into male, the smaller one or microgametes, contains a large diffused nucleus, while the female or megagametocytes are larger with small compact peripheral nucleus. The gametocytes further do not divide and remain in host blood corpuscles, until either they die or ingested by vector i.e mosquito.
In Mosquito (Secondary host – Sporogonic Cycle) A mosquito drinks blood of infected person containing gametocytes. Here development of gametes occurs from gametocytes and this process is known as gametogony or gametogenesis. Due to transfer from warm blooded to cold blooded and change in temperature gametocytes undergo reorganization and form male and female gametes. After that Fertilization takes place where the megagameteform cone like projection as a fertilization cone where its nucleus comes at end. Lashing microgametes penetrate through this cone and syngamy takes place. Here a complete fusion of nuclei and cytoplasm of two gametes occur, resulting in the formation of zygote.The zygote remains rounded and motionless for sometime , then it becomes elongated and motile with gliding or wriggling movement and is known as ookinete. It has dense cytoplasm with number of mitochondria and ribosomes help in protein synthesis. Ookinete penetrates through the wall of midgut(stomach) and settle down. Here it becomes spherical and begins to encyst. The encysted zygote is called Oocyst. Each oocyst now enters a phase of asexual multiplication known as sporogony and form minute, sickle shaped bodies called sporozites, which liberated into haemocoel or body cavity of mosquito and penetrate into the salivary glands of mosquitoes, from where these enters to human with biting by mosquito. In mosquitoes the whole sexual cycle is completed within 10-20 days.
Mode of Parasitism: Plasmodium is an obligate intracellular parasite. It survives by “hiding” inside human cells (liver and blood) to evade the immune system and consumes the host’s hemoglobin for nutrition. Primary Spread: Mosquito-borne (vectorial) transmission. Secondary Spread: Though rare, it can spread via blood transfusions, organ transplants, or shared needles. Congenital malaria occurs when an infected mother passes the parasite to her fetus during pregnancy.
Impact–Hemolytic Anemia: The parasite multiplies inside Red Blood Cells (RBCs) and eventually bursts them. This leads to a severe drop in hemoglobin, causing extreme fatigue, paleness, and shortness of breath. Hepatomegaly: The liver becomes enlarged and inflamed as the parasites multiply within hepatocytes, as the liver is the first organ the parasite hits after the initial mosquito bite. Sometimes it also impacts the Brain (Cerebral Malaria) and this is the most lethal complication, primarily caused by P. falciparum. Encephalopathy: Sequestration of infected cells in the tiny capillaries of the brain causes swelling (edema) and limits oxygen supply. Splenomegaly: The spleen works overtime to filter out the debris of ruptured RBCs and the parasites themselves. This causes the organ to swell significantly. Hemoglobinuria: When massive amounts of hemoglobin are released into the bloodstream from bursting RBCs, it leaks into the urine, turning it dark red or black, as what is historically called “Blackwater Fever.”
Malaria is both a consequence and a cause of poverty. Economic Loss: It is estimated to cost Africa over $12 billion USD annually in lost productivity. Household Burden: In endemic areas, families may spend up to 25% of their annual income on treatment and prevention. Education: It is a leading cause of school absenteeism, affecting the long-term cognitive and economic potential of children.
Symptoms usually appear 10–15 days after a mosquito bite, often mimicking the flu. Malaria typically begins with high fever, shaking chills, and profuse sweating as the body fights the parasite. Patients often experience intense headaches, muscle aches, fatigue, and nausea or vomiting. In some cases, a dry cough or abdominal pain occurs. Symptoms usually appear in cycles, and without prompt treatment, they can progress to severe complications like jaundice or seizures.
Treatment- ACTs (Artemisinin-based Combination Therapies)The standard, most effective treatment for P. falciparum, combining an artemisinin derivative with another partner drug to kill parasites quickly. Chloroquine used for P. vivax malaria, provided the parasite is still sensitive to it. Other Medications: Atovaquone-proguanil (Malarone), quinine, doxycyline, and clindamycin. Vaccines: As of 2026, two vaccines—RTS,S/AS01 (Mosquirix) and the highly effective. R21/Matrix-M—are being rolled out across 24+ countries. The R21 vaccine has shown up to 75% efficacy in trials.
As of 2026, India is in a critical “transition phase” of its malaria journey. The country has shifted from being one of the highest-burden nations to a global leader in malaria reduction, aiming for zero indigenous cases by 2027 and a malaria-free status by 2030. According to the World Malaria Report 2025 and data from the Ministry of Health and Family Welfare (MoHFW), India has achieved historic milestones, as cases of malaria has declined by approximately 80.5% between 2015 and 2023, deaths plummeted by 78.3% in the same period.
The Indian government operates under two core blueprints to ensure elimination: National Framework for Malaria Elimination (2016–2030) in which states are categorised based on their Annual Parasite Incidence (API) and National Strategic Plan (2023–2027) This current plan focuses on shifting from “control” to “elimination.” It emphazises 1–3–7 Surveillance Strategy: Notification within 1 day, investigation within 3 days, and response within 7 days; Test-Treat-Track: Mandatory testing of all fever cases and complete radical treatment.
- Pancreas: An important and Mixed gland - July 2, 2026
- Fossil: Window into Earth - July 2, 2026
- Life Cycle of Malarial Parasites and Pathogenecity. - February 13, 2026
No Comments